Viewing data from:

MILI

ANDA

ETHINYL ESTRADIOL; NORGESTIMATE | A205449 | AUROBINDO PHARMA LTD

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Mili (2023)

Total Spending

$187K

Total Claims

6,429

Beneficiaries

2,041

Avg Cost/Unit

$0.45

Spending Trend

$75K(2019)→$72K(2020)→$211K(2021)→$199K(2022)→$187K(2023)

YoY Change:-8.6%

5yr CAGR:-3.3%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 0.035MG;0.25MG

0 patents0 exclusivities▴

TABLET;ORAL-28 | Approved: Jul 7, 2016

No patent or exclusivity listings for this strength.